Alkermes

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alkermes and other ETFs, options, and stocks.

About ALKS

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. 

CEO
Richard F. Pops
CEORichard F. Pops
Employees
2,050
Employees2,050
Headquarters
Dublin, Dublin
HeadquartersDublin, Dublin
Founded
2011
Founded2011
Employees
2,050
Employees2,050

ALKS Key Statistics

Market cap
5.84B
Market cap5.84B
Price-Earnings ratio
24.69
Price-Earnings ratio24.69
Dividend yield
Dividend yield
Average volume
3.63M
Average volume3.63M
High today
$36.48
High today$36.48
Low today
$34.00
Low today$34.00
Open price
$35.47
Open price$35.47
Volume
4.76M
Volume4.76M
52 Week high
$36.48
52 Week high$36.48
52 Week low
$25.17
52 Week low$25.17

Stock Snapshot

With a market cap of 5.84B, Alkermes(ALKS) trades at $34.00. The stock has a price-to-earnings ratio of 24.69.

On 2026-04-01, Alkermes(ALKS) stock moved within a range of $34.00 to $36.48. With shares now at $34.00, the stock is trading 0.0% above its intraday low and -6.8% below the session's peak.

Trading activity shows a volume of 4.76M, compared to an average daily volume of 3.63M.

The stock's 52-week range extends from a low of $25.17 to a high of $36.48.

The stock's 52-week range extends from a low of $25.17 to a high of $36.48.

ALKS News

Simply Wall St 25m
Alkermes Narcolepsy Trials Spark Interest In Growth And Valuation Upside

Alkermes (NasdaqGS:ALKS) has begun Phase 3 clinical trials for alixorexton, its orexin 2 receptor agonist for narcolepsy type 1 and type 2. The late stage Bril...

Alkermes Narcolepsy Trials Spark Interest In Growth And Valuation Upside
TipRanks 10h
Alkermes announces initiation of Brilliance Studies

Alkermes (ALKS) announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in a...

TipRanks 1d
Alkermes jumps 15% on renewed biotech M&A buzz, says Leerink

Alkermes (ALKS) rose 15% after Eli Lilly (LLY) agreed to acquire Centessa Pharmaceuticals (CNTA), reflecting renewed M&A momentum in biotech, Leerink tells inve...

Analyst ratings

82%

of 17 ratings
Buy
82.4%
Hold
17.6%
Sell
0%

More ALKS News

Simply Wall St 7d
Is Alkermes Offering Value After Recent Share Price Swings And DCF Upside Estimates

Wondering if Alkermes at around US$29.37 is a bargain or already pricing in its prospects? This article walks through how the numbers stack up so you can judge...

Is Alkermes Offering Value After Recent Share Price Swings And DCF Upside Estimates

People also own

Based on the portfolios of people who own ALKS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.